AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00621764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)
Description: ≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
Study NCT04164264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
Study NCT05179564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iohexol administration
Description: IV injection of weight-dependent low dose of iohexol at time 0
Study NCT05179564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iohexol blood sampling
Description: Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
Study NCT00121485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support
Study NCT00121485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support
Study NCT00659009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced barometric pressure
Description: Sleep in reduced barometric pressure environment.
Study NCT00659009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea level equivalent barometric pressure
Description: Sleep in barometric pressure equivalent to sea level.
Study NCT02331927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression.
Study NCT02306525 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic surgery of the hip joint
Description: Arthroscopic treatment of Femoroacetabular Impingement
Study NCT00615420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: manuka honey
Description: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
Study NCT00615420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
Study NCT03704233 — intervention group
Intervention type: PROCEDURE
Intervention: Transbronchial cryobiopsy
Description: Transbronchial cryobiopsy procedure
Study NCT03883659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
Study NCT03883659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional paper hangouts
Description: patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
Study NCT01673373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCAST™ Rx Stent System
Description: All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
Study NCT01116661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevuline Acid (ALA)
Description: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
Study NCT00242658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Intervention
Description: Tailored physical activity computer reports will be provided to patients and physicians.
Study NCT03024151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comthyroid
Description: T4/T3 combination replacement
Study NCT03024151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid
Description: T4 mono replacement
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00470223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study NCT00470223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00470223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 modified release tablet
Description: At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 blend, hard capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 API, hard capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 soft capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 32731 gastro-resistant capsule
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study NCT01378247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Nursing
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
Study NCT01697605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study NCT01596985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation using the PlasmaJet system
Description: Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
Study NCT00550030 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB-311nm radiation
Description: UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
Study NCT00550030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: no UV exposure
Study NCT03714828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions - week 1-2
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient.
Study NCT03714828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 3wks after 1st injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses.
Study NCT03714828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 2wks after 2nd injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Study NCT03714828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of TVEC into target lesions 2wks after 3rd injection
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Study NCT04358055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WET® gel
Description: In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
Study NCT01333397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 (single treatment cycle)
Study NCT01333397 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: I.M. on day 1 (single treatment cycle)
Study NCT01333397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. on day 1 (single treatment cycle)
Study NCT00773292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
Study NCT00468572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affectionate Writing
Description: Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
Study NCT00468572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningless Writing
Description: Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
Study NCT01857466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Floseal
Study NCT01857466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Study NCT03540147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hokanson Cuffs
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
Study NCT03540147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
Study NCT03540147 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BStrong Bands
Description: Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
Study NCT03959020 — intervention group
Intervention type: PROCEDURE
Intervention: Anti-reflux surgery
Description: Anti-reflux surgery for verified GERD
Study NCT03415750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Conversion from Mycophenolate mofetil to Everolimus
Study NCT03415750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients will remain in Tacrolimus + Mycophenolate mofetil
Study NCT03415750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT03415750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT04396990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study NCT04396990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study NCT01763190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT01596985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy
Description: Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C).
Study NCT02750592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Description: Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
Study NCT04611750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036
Description: AD036 will be given for 14 days
Study NCT04611750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 14 days
Study NCT00671307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu-pGelsolin
Description: IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
Study NCT01510782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 655064
Description: intravenous infusion of escalating doses
Study NCT01510782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 655064
Description: subcutaneous injection of escalating doses
Study NCT01510782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: intravenous infusion of escalating doses
Study NCT01510782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection of escalating doses
Study NCT03940131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
Study NCT00671307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control given as IV infusion over 1 hour
Study NCT03794388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Application of capsaicin patches at 8% on painful area
Study NCT03794388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Taking Pregabalin tablets
Study NCT03626376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily
Description: Treatment used in standard of care
Study NCT03626376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Description: Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
Study NCT01629368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Multiple doses of carbamazepine
Study NCT01629368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523
Study NCT00322946 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN4delta30-4995
Study NCT04139720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-book
Description: sexual harassment prevention via education e-book
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Study NCT03812198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Study NCT02084472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baby oil
Description: patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
Study NCT02084472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: petroleum jelly
Description: patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser